SCIO-469 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	3

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00508768 (ClinicalTrials.gov)	August 2005	27/7/2007	A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid Arthritis	A Randomized, Double-Blind, Parallel-Group, Pharmacokinetic Study of Oral SCIO-469 (90 mg qd and 30 mg Tid) in Female Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Oral SCIO-469 capsule	Scios, Inc.	NULL	Completed	18 Years	N/A	Female	16	Phase 1	NULL
2	NCT00089921 (ClinicalTrials.gov)	July 2004	17/8/2004	SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine	Arthritis, Rheumatoid	Drug: SCIO-469;Drug: Placebo	Scios, Inc.	NULL	Completed	18 Years	N/A	Both	302	Phase 2	United States
3	NCT00043732 (ClinicalTrials.gov)	July 2002	12/8/2002	Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients in Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: SCIO-469	Scios, Inc.	NULL	Completed	18 Years	N/A	Both	120	Phase 2	United States